Independent Sens. Bernie Sanders of Vermont and Angus King of Maine have introduced a bill that would ban pharmaceutical ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. | ...

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion (OPDP). | Sprout ...

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

Right after Robert F. Kennedy Jr. secured confirmation as U.S. | The Department of Health and Human Services has removed all ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...

Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S.

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million verdict ...